Skip to content
DataLookout
Menu

NCT07948928

EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Start date changed from estimate of Nov 2026 to Oct 28, 2026
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication
Timeframe: At the first qualifying primary care visit during the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed a CGM
Timeframe: At the first qualifying primary care visit during the study period, up to 3 months

Secondary (3)

Provider Response to the OPA alert
Reasons for Declining the OPA alert
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication by Patient Characteristics

Arms and interventions

Our Practice Advisory (OPA) AlertExperimental

Education will be provided on the use of the alerts to PCPs in the intervention group. Providers will continue using clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Usual Care (UC)No intervention

Providers continue usual care, with no alert. Providers will use clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Other: Our Practice Advisory (OPA) alert

Sites

1 site in 1 country

  • Montefiore Medical CenterThe Bronx, New York, United States